Can Modicare Reshape India’s Health Care Paradigm?

India’s new government-funded health care program expects to expand access to treatment to more than 100 million families. Can it effectively deliver on its promise and also materially expand opportunities for hospitals and pharma?

Modicare
India’s mammoth health assurance scheme offers hope of better health care for over 100 million families • Source: Shutterstock

An auto rickshaw driver who suffered a heart attack but could not afford surgery was the first beneficiary from the state of Haryana to undergo an angioplasty under India’s Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana (PMJAY). In another case, a wage labourer in Uttar Pradesh state, underwent a free cholecystectomy to get a stone removed from his gall bladder.

Many such heart-warming stories featured in recent tweets by Dr. Indu Bhushan, the man at the helm of seeing through...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Market Access

How To Decarbonize Pharma R&D

As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.

IV-MarketAccess (Premium-1): Stimulant Medications Don’t Cause Psychosis, New Study Finds

 
• By 

Instead, the new study found children with more severe attention and hyperactivity issues or other mental health conditions such as anxiety were more likely to be medicated for ADHD.

[Test]With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By 

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

In Search Of Rare Disease Treatments, Nonprofits Can Lead the Charge

 
• By 

Nonprofits are finding new ways to address market gaps and develop treatments for rare diseases with little commercial attraction.

More from In Vivo

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

In Vivo’s 2026 Rising Leaders-Part 1

 
• By 

The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.

XXXXtesting

 
• By 

XXXXtesting